In our results, it is confirmed that the expression of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F in tumor immune subtypes is statistically significant, especially in BRCA; there may be a potential microenvironmental regulation mechanism that remains to be investigated. This evidence concerns the gene IL25 and neoplasm.